Cellectricon Files Patent Infringement Suit Against Fluxion Biosciences
News Feb 01, 2010
Cellectricon AB today announced that it has resumed its litigation against Fluxion Biosciences, Inc. Cellectricon filed the lawsuit in July 2009 in the United States District Court for the Northern District of California alleging infringement of several United States patents issued or licensed to Cellectricon for microfluidic technology used in Cellectricon’s ion channel drug screening solution, the Dynaflow®HT System.
Cellectricon’s U.S. Patents Nos. 7,390,650, 7,470,518 and 7,563,614 have been asserted in the litigation, as well as U.S. Patent No. 5,376,252, which is owned by Gyros, and licensed to Cellectricon.
Annelie Skafte Persson, Cellectricon’s Chief Executive Officer, said “Cellectricon invents and develops advanced cell-based microfluidic screening solutions for applications in drug discovery and basic research. Cellectricon has an extensive intellectual property portfolio with novel cell-based screening technologies based on fifteen years of world-renowned research. To ensure a fair return on our research and development efforts we must protect our intellectual property and we will take all necessary steps to prevent its unauthorized use.”
Cellectricon’s Chairman Lars-Eric Utterman added “Cellectricon is a highly innovative company which has successfully launched several advanced screening systems on the life science market. Today’s litigation is a strategic step to defend Cellectricon’s intellectual property from being infringed.”
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Blood-vessel-on-a-chip Provides Insight into Novel Anti-Inflammatory Drug CandidateNews
Researchers have discovered that synthetic APC-mimicking small molecules called “parmodulins” provide anti-inflammatory and anti-thrombotic protection to endothelial cells on par with APC’s without interfering with normal blood clotting and coagulation, making them attractive new drug candidates.READ MORE